Detroit Free Press: Feds approve University of Michigan stem cell line
By Robin Erb, Detroit Free Press Medical Writer
A University of Michigan stem cell line derived from a 5-day-old embryo has been approved for federally funded research -- a move that strengthens the state's foothold in the embryonic stem cell science world.
It's also a federal stamp of approval that Michigan's informed consent process -- an agreement from parents who donate embryos to such research -- is ethically and legally sound, said Sue O'Shea, codirector of the Consortium for Stem Cell Therapies.
"This opens the door for all kinds of spin-offs and companies," she said. "It has been such a long struggle."
By Robin Erb, Detroit Free Press Medical Writer
A University of Michigan stem cell line derived from a 5-day-old embryo has been approved for federally funded research -- a move that strengthens the state's foothold in the embryonic stem cell science world.
It's also a federal stamp of approval that Michigan's informed consent process -- an agreement from parents who donate embryos to such research -- is ethically and legally sound, said Sue O'Shea, codirector of the Consortium for Stem Cell Therapies.
"This opens the door for all kinds of spin-offs and companies," she said. "It has been such a long struggle."
In November 2008, Michigan voters approved a constitutional amendment, Proposal 2, that permitted researchers to use surplus embryos. There were protests from opponents who say the research destroys the embryos.
Gary Smith, the other codirector of the consortium, coaxed UM4-6 into an immortal mass of cells after drawing a tiny clump of about 30 cells from an embryo in 2010. The cells, nurtured in what Smith called "a very precise culture and the right nutrients," continued to replicate into millions, even as they remained in their embryonic state.
On Monday, UM4-6 appeared on the U.S. National Institutes of Health registry as its 147th available line, Smith said.
Other cell lines were contributed by Harvard and Stanford universities, the University of California, Los Angeles, and others.
Ed Rivet, legislative director of Right to Life of Michigan and an opponent of Proposal 2, said UM4-6's inclusion on the national registry wasn't a surprise. But proponents of embryonic stem cell research predicted "pent-up" research demand and an economic boon if the proposal passed, he said.
"One stem cell line after 3 1/2 years isn't a whole lot of product to talk about," he said.
UM4-6 is believed to be disease-free. In contrast, two other lines at U-M that were submitted to the national registry are disease-specific. Eight other lines -- three genetically normal and five with genetic defects -- are in development.
The UM4-6 cells, which will be a control line when comparing diseased cells, will be maintained by U-M, Smith said.
Though the university will charge a minimal fee to recoup costs for maintaining the line, the economic boost comes from "the research (UM4-6) enables and the discoveries that will occur," Smith said.
Contact Robin Erb: 313-222-2708 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Link to original story here.
Help Us Make A Difference. Make A Donation That Could Save Lives.
Taubman Emerging Scholars Program
Request for applications
Applications are being accepted for the Taubman Institute Emerging Scholars Program.
The applicant must be a junior member of the faculty at the University of Michigan; generally, that means holding an assistant professor title. The applicant must have either an M.D. or an M.D./Ph.D. It is required that candidates both conduct basic research and treat patients.
Applicants should submit a two-to-three page research proposal, as well as a current CV. Priority will be given to proposals involving translational research. Please submit material to This e-mail address is being protected from spambots. You need JavaScript enabled to view it. . The deadline is May 7, 2012.
Young Friends host festive NYC fundraiser
Reception introduced scholar candidate Dr. Parag Patil
About 125 supporters of cutting-edge medical research mixed socializing and science May 9 at a cocktail party in Manhattan hosted by the Young Friends of the Taubman Institute's New York City chapter.
The event introduced Dr. Parag Patil, a University of Michigan physician-researcher and a prospective Young Friends Emerging Scholar. Here's a clip from Dr. Patil's appearance on the TV program "The Doctors," where he demonstrates how deep-brain stimulation has helped a patient with Parkinson's disease.
Emerging Scholars are early-career clinician-scientists who show great promise in research aimed at new cures or treatments; through the Taubman Institute, donors support them with three-year grants while their labs earn the credentials to win broader funding support.
The Young Friends event, which raised a significant contribution toward the Emerging Scholars program, was held at the ABC Carpet & Home showrooms at 888 Broadway, Attendees enjoyed cocktails, appetizers, a silent auction and a presentation by Dr. Patil. The silent auction included jewelry, fashion items, a Botox consultation and treatment, Morgan Hotel Group rooms and the opportunity to bid on a meeting and photo with former President William Jefferson Clinton.
Taubman Research
Dr. Max Wicha: Some treatments actually increase cancer stem cells
Avastin and Sutent have been found to increase the growth of breast cancer stem cells in mice, according to Taubman Scholar Dr. Max Wicha, director of the U-M Comprehensive Cancer Center.
